Martin Mackay joined New Leaf as a Senior Advisor in 2018. He currently serves in an executive leadership role at Rallybio, a New Leaf portfolio company, overseeing all research and non-research functions. He has more than 30 years of experience in drug discovery and development, overseeing multinational teams working on hundreds of programs. Most recently, he was Executive Vice President, Global Head of R&D at Alexion Pharmaceuticals, where he oversaw the development of multiple pre-clinical and clinical programs, resulting in new ultra-rare indications, for Soliris® (eculizumab), as well as new approvals for the ultra-orphan therapies Strensiq® (asfotase alfa) and Kanuma® (sebelipase alfa).
Prior to Alexion, Martin served as President, Research and Development at AstraZeneca, reporting directly to the CEO, where he led all R&D functions on a global basis, from discovery research through clinical development, regulatory affairs and related functions. Prior to AstraZeneca, he held positions of increasing responsibility at Pfizer, rising to the position of President, Head of Pfizer Pharmatherapeutics, R&D, working across nine therapeutic areas and reporting to the CEO and Chairman.
Martin serves on the Boards of Directors of Charles River Laboratories and Novo Nordisk. He obtained a First Class Honours degree in Microbiology from Heriot-Watt University and his PhD in molecular genetics from the University of Edinburgh, Scotland.